— Fundamental Stock Analysis and Report Card
Located in Rahway, NJ, US. Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q1 2026 Total ($) | Q1 2026 Margin (%) | |
|---|---|---|
| Revenue | 16.3b +667.0m +4.3% | |
| Gross Income | 13.3b +1.6b +13.7% | 82% +6.8pp +9.0% |
| EBITDA | -2.0b -9.3b -127.6% | -12% -59.2pp -126.5% |
| Operating Income | -1.9b -8.6b -128.1% | -12% -54.5pp -126.9% |
| Net Income | -4.2b -9.3b -183.5% | -26% -58.6pp -180.1% |
| Earnings Per Share | -1.72 -3.7 -185.6% | |
| Operating Cash Flow | 3.9b +1.4b +56.7% | 24% +8.1pp +50.3% |
| Free Cash Flow | 2.9b +1.8b +149.7% | 18% +10.5pp +139.5% |
| Research & Development | 12.6b +9.4b +302.6% | 77% +57.1pp +286.1% |